340B faces potential new Oversight

Recent news from the Trump administration suggests that oversight of the 340B federal drug discount program could move to the Centers for Medicare and Medicaid Services
(CMS). The CMS has a more aggressive history with the drug pricing program, having limited Medicaid reimbursement for 340B drugs in the past and limiting the rebates that providers can collect on those drugs. Many critics of the program believe that more oversight would be a good thing, limiting the profits that 340B covered entities can make and helping to pass the benefits of the program back to the patients it’s meant to protect. Our Health Equity advocates for reforms in the 340B program to ensure that all Americans have access to the medicines they need at a reasonable price. Read more here.